Trastuzumab regimens for HER2-overexpressing metastatic breast cancer.
作者： David R. Spigel , Harold J. Burstein
关键词: Breast cancer 、 Metastatic breast cancer 、 Medicine 、 Clinical trial 、 Internal medicine 、 Combination therapy 、 Oncology 、 Monoclonal 、 Chemotherapy 、 Innovative Therapies 、 Trastuzumab
摘要: Combination treatment with chemotherapy and trastuzumab is now standard therapy for the first-line of women HER2-overexpressing metastatic breast cancer. has been shown to increase response rates, time progression, quality life, overall survival such patients. Several combination regimens have developed, newer recently reported are being studied in ongoing clinical trials. Newer trastuzumab-based include triplet combinations taxanes platinum salts combining other innovative therapies. Among increasing array available combinations, several proven appropriate therapy. To date, optimal region not defined. Moreover, questions remain regarding best scheduling, duration, use at disease progression. This review briefly outlines evolving role
metapress.com参考文章(29)
Joyce O'Shaughnessy, Svetislava J. Vukelja, Thomas Marsland, Gary Kimmel, Suresh Ratnam, John Pippen, Phase II Trial of Gemcitabine plus Trastuzumab in Metastatic Breast Cancer Patients Previously Treated with Chemotherapy: Preliminary Results Clinical Breast Cancer. ,vol. 3, pp. 17- 20 ,(2002) , 10.3816/CBC.2002.S.004
P. C. Roche, V. J. Suman, R. B. Jenkins, N. E. Davidson, S. Martino, P. A. Kaufman, F. K. Addo, B. Murphy, J. N. Ingle, E. A. Perez, Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831 Journal of the National Cancer Institute. ,vol. 94, pp. 855- 857 ,(2002) , 10.1093/JNCI/94.11.855
S. Paik, J. Bryant, E. Tan-Chiu, E. Romond, W. Hiller, K. Park, A. Brown, G. Yothers, S. Anderson, R. Smith, D. L. Wickerham, N. Wolmark, Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. Journal of the National Cancer Institute. ,vol. 94, pp. 852- 854 ,(2002) , 10.1093/JNCI/94.11.852
Andrew D. Seidman, Monica N. Fornier, Francisco J. Esteva, Lee Tan, Stamatina Kaptain, Ariadne Bach, Katherine S. Panageas, Crispinita Arroyo, Vicente Valero, Violante Currie, Teresa Gilewski, Maria Theodoulou, Mary Ellen Moynahan, Mark Moasser, Nancy Sklarin, Maura Dickler, Gabriella D’Andrea, Massimo Cristofanilli, Edgardo Rivera, Gabriel N. Hortobagyi, Larry Norton, Clifford A. Hudis, Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification Journal of Clinical Oncology. ,vol. 19, pp. 2587- 2595 ,(2001) , 10.1200/JCO.2001.19.10.2587
Charles L Vogel, Melody A Cobleigh, Debu Tripathy, John C Gutheil, Lyndsay N Harris, Louis Fehrenbacher, Dennis J Slamon, Maureen Murphy, William F Novotny, Michael Burchmore, Steven Shak, Stanford J Stewart, Michael Press, Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 20, pp. 719- 726 ,(2002) , 10.1200/JCO.20.3.719
G. Lunardi, M.O. Vannozzi, C. Bighin, L. Del Mastro, I. Stevani, G. Schettini, M. Venturini, Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients Annals of Oncology. ,vol. 14, pp. 1222- 1226 ,(2003) , 10.1093/ANNONC/MDG350
Stephen Chan, Kay Friedrichs, Daniel Noel, Tamàs Pintér, Simon Van Belle, Daniel Vorobiof, Ricardo Duarte, Miguel Gil Gil, Istvan Bodrogi, Elizabeth Murray, Louise Yelle, Gunter von Minckwitz, Stefan Korec, Peter Simmonds, Franco Buzzi, Rosario González Mancha, Gary Richardson, Euan Walpole, Monica Ronzoni, Michael Murawsky, May Alakl, Alessandro Riva, John Crown, Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 17, pp. 2341- 2354 ,(1999) , 10.1200/JCO.1999.17.8.2341
Francisco J. Esteva, Vicente Valero, Daniel Booser, Laura T. Guerra, James L. Murray, Lajos Pusztai, Massimo Cristofanilli, Banu Arun, Bita Esmaeli, Herbert A. Fritsche, Nour Sneige, Terry L. Smith, Gabriel N. Hortobagyi, Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 20, pp. 1800- 1808 ,(2002) , 10.1200/JCO.2002.07.058
George Fountzilas, Evangelia Razis, Dimitrios Tsavdaridis, Maria Karina, Stefanos Labropoulos, Christos Christodoulou, Dimitrios Mavroudis, Helen Gogas, Vassilios Georgoulias, Dimosthenis Skarlos, Continuation of Trastuzumab Beyond Disease Progression Is Feasible and Safe in Patients with Metastatic Breast Cancer: A Retrospective Analysis of 80 Cases by the Hellenic Cooperative Oncology Group Clinical Breast Cancer. ,vol. 4, pp. 120- 125 ,(2003) , 10.3816/CBC.2003.N.017
M D Pegram, A Lipton, D F Hayes, B L Weber, J M Baselga, D Tripathy, D Baly, S A Baughman, T Twaddell, J A Glaspy, D J Slamon, Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Journal of Clinical Oncology. ,vol. 16, pp. 2659- 2671 ,(1998) , 10.1200/JCO.1998.16.8.2659